Skip to main content
SpringerLink
Log in

New Treatment Approaches to Myasthenia Gravis

  • Practical Therapeutics
  • Published:
Drugs Aims and scope Submit manuscript

Summary

Myasthenia gravis is an autoimmune disorder in which rieuromuscular transmission is impaired by autoantibodies to the acetylcholine receptor (AChR). There are 3 varieties of generalised myasthenia with differing genetic susceptibilities.There is also a purely ocular form in which the weakness is confined to the extraocular muscles, and a neonatal variety which occurs in 20% of babies born to myasthenic mothers due to transplacental passage of the acetylcholine receptor antibody. Another variety of myasthenia occurs several months after treatment with D-penicillamine.

The role of the thymus is suggested by abnormal histology in patients with myasthenia and by the beneficiai effects of thymectomy in more than two-thirds of patients. Thymectomy is indicated in most patients unless the symptoms are minimal or the weakness is confined to the extraocular muscles.

Most patients require treatment with anticholinesterase drugs to prolong the action of acetylcholine at the muscle end-plate. Overdosage of these drugs can provoke a cholinergic weakness.

Remissions can be achieved with corticosteroids in 80% of patients. Immunosuppression with azathioprine is used mainly in patients who do not respond to thymectomy or in those patients who are considered unsuitable for operation. Plasma exchange can cause a rapid but temporary improvement in myasthenia, and has no long term place in its treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Aquilonius SM, Eckernas SA, Hartvig P, Lindstrom B, Osterman PO. Pharmacokinetics and oral bioavailability of pyridostigmine in man. European Journal of Clinical Pharmacology 48: 423–428,1980

    Article  Google Scholar 

  • Aquilonius SM, Eckernas SA, Hartvig P, Lindstrom B, Osterman PO. Clinical pharmacology of neostigmine and pyridostigmine in patients with myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry 46: 929–935, 1983

    Article  CAS  Google Scholar 

  • Argov Z, Mastalgia FL. Disorders of neuromuscular transmission caused by drugs. New England Journal of Medicine 301: 409–413, 1979

    Article  PubMed  CAS  Google Scholar 

  • Arsura EL, Bick A, Brunner NG, Namba T, Grob D. High dose intravenous immunoglobulin in the management of myasthenia gravis. Archives of Internal Medicine 146: 1365–1368, 1986

    Article  PubMed  CAS  Google Scholar 

  • Bell J, Rasserti L, Smoot S. HLA-DQ beta chain polymorphism linked to myasthenia gravis. Lancet 1: 1058–1060, 1986

    Article  PubMed  CAS  Google Scholar 

  • Bingle JP, Rutherford JD, Woodrow P. Continuous subcutaneous neostigmine in the management of severe myasthenia gravis. British Medical Journal 1: 1050, 1979

    Article  PubMed  CAS  Google Scholar 

  • Borel JF. Animal experiments with cyclosporin. Triangle 23: 153–158, 1984

    Google Scholar 

  • Buckingham JM, Howard Jr FM, Bernatz PE, Spencer Payne W, Harrison EG, et al. The value of thymectomy in myasthenia gravis: a computer assisted matched study. Annals of Surgery 184: 453–458, 1976

    Article  PubMed  CAS  Google Scholar 

  • Calvey TN, Chan K. Plasma pyridostigmine levels in patients with myasthenia gravis. Clinical Pharmacology and Therapeutics 21: 187–193, 1977

    PubMed  CAS  Google Scholar 

  • Cohen DJ, Loestscher R, Rubin MF, Tilney NL, Carpenter CB, et al. Cyclosporine: a new immunosuppressive agent for organ transplantation. Annals of Internal Medicine 101: 667–682, 1984

    PubMed  CAS  Google Scholar 

  • Compston DA, Vincent A, Newson-Davis J, Batchelor JR. Clinical pathological HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103: 579–601, 1980

    Article  PubMed  CAS  Google Scholar 

  • Fonseca VF, Havard CWH. Long term treatment of myasthenia gravis with azathioprine. Postgraduate Medical Journal, in press, 1989

  • Garlep MJ, Dawkins RL, Christiansen FT. HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis. British Medical Journal 286: 338–341, 1983

    Article  Google Scholar 

  • Havard CWH, Scadding GK. Myasthenia gravis: pathogenesis and current concepts in management. Drugs 26: 174–184, 1983

    Article  PubMed  CAS  Google Scholar 

  • Kennedy FS, Moersch FP. Myasthenia gravis: a clinical review of 87 cases observed between 1925 and the early part of 1932. Canadian Medical Association Journal 37: 216, 1937

    PubMed  CAS  Google Scholar 

  • Kornfeld P, Horowitz SH, Genkins G, Papatestas A. Myasthenia gravis unmasked by antiarrhythmic agents. Mt Sinai Journal of Medicine 43: 10–14, 1976

    CAS  Google Scholar 

  • Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates and diagnostic value. Neurology 26: 1054–1059, 1976

    Article  PubMed  CAS  Google Scholar 

  • Mertens HG, Hertel G, Reuther P, Ricker K. Effect of immunosuppressive drugs (azathioprine). Annals of the New York Academy of Sciences 377: 691–699, 1981

    Article  PubMed  CAS  Google Scholar 

  • Mier A, Havard CWH. Diaphragmatic myasthenia in mother and child. Postgraduate Medical Journal 61: 725–727, 1985

    Article  PubMed  CAS  Google Scholar 

  • Murphy J, Murphy SF. Myasthenia gravis in identical twins. Neurology 36: 78–80, 1986

    Article  PubMed  CAS  Google Scholar 

  • Newsom-Davis J, Wilson SG, Vincent A, Ward CD. Long term effects of repeated plasma exchange in myasthenia gravis. Lancet 1: 464–468, 1979

    Article  PubMed  CAS  Google Scholar 

  • Noda M, Furutani Y, Takahashi H, Toyosato H, Tanabe T, et al. Cloning and sequence analysis of calf cDNA and human genomic DNA encoding α-subunit precursor of muscle acetylcholine receptor. Nature 305: 818–823, 1983

    Article  PubMed  CAS  Google Scholar 

  • Osterhuis HJ. The natural history of myasthenia gravis and various procedures influencing its course. In Satoyoshi E (Ed.) Myasthenia gravis: pathogenesis and treatment, pp. 361–371, University of Tokyo Press, Tokyo, 1981

    Google Scholar 

  • Pascuzzi RM, Coslett HB, Johns TR. Long term corticosteroid treatment of myasthenia gravis: report of 116 patients. Annals of Neurology 15: 291–298, 1984

    Article  PubMed  CAS  Google Scholar 

  • Pirofsky B. The effect of anti-thymocyte antiserum in progressive myasthenia gravis. Annals of the New York Academy of Sciences 377: 779–785, 1981

    Article  PubMed  CAS  Google Scholar 

  • Plauché WC. Myasthenia gravis in pregnancy: an update. American Journal of Obstetrics and Gynecology 135(5): 691–697, 1979

    PubMed  Google Scholar 

  • Rowland LP. Controversies about the treatment of myasthenia gravis. Journal of Neurology, Neurosurgery and Psychiatry 43: 644–659, 1980

    Article  CAS  Google Scholar 

  • Rowland LP, Hoefer PRA, Aranow HJR, Merritt HH. Fatalities in myasthenia gravis: a review of 39 cases with 26 autopsies. Neurology 6: 307–326, 1956

    Article  PubMed  CAS  Google Scholar 

  • Tindall RS, Rollins JA, Phillips JJ, Greenlee RG, Wells L, et al. Preliminary results of a double-blind, randomised, placebo-controlled trial of cyclosporine in myasthenia gravis. New England Journal of Medicine 316: 719–724, 1987

    Article  PubMed  CAS  Google Scholar 

  • White MC, de Silva P, Havard CWH. Plasma pyridostigmine levels in myasthenia gravis. Neurology 31: 145–150, 1981

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Royal Free Hospital, Pond Street, Hampstead, London, NW3 2QG, England

    C. W. H. Havard & V. Fonseca

Authors
  1. C. W. H. Havard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Havard, C.W.H., Fonseca, V. New Treatment Approaches to Myasthenia Gravis. Drugs 39, 66–73 (1990). https://doi.org/10.2165/00003495-199039010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199039010-00006

Keywords

Search

Navigation